# China NMPA Drug Inspection - Hebei Shunquanlong Pharmaceutical Co., Ltd. - rush

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-shunquanlong-pharmaceutical-co-ltd/ebeee3ca-b727-4360-b908-770452d0f976/
Source feed: China

> China NMPA drug inspection for Hebei Shunquanlong Pharmaceutical Co., Ltd. published September 29, 2021. Drug: rush. The Hebei Provincial Drug Administration issued Drug Quality Bulletin No. 2 on September 29, 2021, detailing results fro

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hebei Province Drug Quality Bulletin (2021 Drug Supervision and Sampling Inspection No. 2)
- Company Name: Hebei Shunquanlong Pharmaceutical Co., Ltd.
- Publication Date: 2021-09-29
- Drug Name: rush
- Inspection Finding: The "Properties" item does not meet the requirements.
- Action Taken: The relevant drug regulatory authorities have taken control measures such as sealing and seizing in accordance with the law; they have filed cases to investigate illegal acts of producing and selling substandard drugs, and have taken necessary risk control measures, and will make the results public within three months.
- Summary: The Hebei Provincial Drug Administration issued Drug Quality Bulletin No. 2 on September 29, 2021, detailing results from its province-wide drug supervision and sampling inspection plan. The inspection identified Hebei Shunquanlong Pharmaceutical Co., Ltd. as having produced a batch of Juncus effusus (batch number 20160301) that failed to meet quality standards. Testing conducted by the Tangshan Municipal Food and Drug Comprehensive Inspection and Testing Center specifically found the drug non-compliant regarding its physical appearance. Operating under the regulatory framework of the Drug Administration Law of the People's Republic of China, the administration has implemented strict enforcement measures. Local regulatory bodies have already seized and sealed the substandard products to prevent further use. Required actions include a formal investigation and prosecution of the manufacturer for the production and sale of substandard drugs. Furthermore, the company must implement risk control measures, and the results of the investigation must be publicly announced within three months. Authorities are also tasked with tracing the source of any potentially counterfeit materials and referring any suspected criminal activity to public security departments for further prosecution.

Company: https://www.globalkeysolutions.net/companies/hebei-shunquanlong-pharmaceutical-co-ltd/967fb4fe-d225-42ab-b88a-f194187fdf7a/